/
SDGR
$17.53+$0.33 (+1.96%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.3B
75M shares
52-week range
$10.95 – $23.75
51% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-58.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.6M | $85.5M | $108.1M | $137.9M | $181.0M | $216.7M | $207.5M | $255.9M |
| Cost of revenue | $23.7M | $36.5M | $44.6M | $72.3M | $79.9M | $76.0M | $75.5M | $113.3M |
| Gross profit | $42.9M | $49.1M | $63.5M | $65.6M | $101.0M | $140.7M | $132.1M | $142.6M |
| Gross margin | 64.4% | 57.4% | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| R&D | $34.5M | $39.4M | $64.7M | $90.9M | $126.4M | $181.8M | $201.8M | $173.1M |
| Operating income | −$28.0M | −$38.7M | −$60.9M | −$111.4M | −$146.8M | −$177.4M | −$209.3M | −$166.9M |
| EBITDA | −$25.1M | −$35.1M | −$57.3M | −$98.0M | −$144.8M | $48.5M | −$179.6M | −$96.3M |
| Net income | −$28.4M | −$24.6M | −$24.5M | −$100.4M | −$149.2M | $40.7M | −$187.1M | −$103.3M |
| Net margin | -42.7% | -28.7% | -22.6% | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% |
| EPS (diluted) | -0.59 | -0.41 | -0.44 | -1.43 | -2.10 | 0.54 | -2.57 | -1.41 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $235M | $-2.03 | $-2.88–$-1.12 | 4 |
| 2027 | $265M | $-1.25 | $-2.65–$0.53 | 4 |
| 2028 | $323M | $-0.07 | $-0.65–$0.88 | 3 |
| 2029 | $372M | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Schrodinger, Inc. Common Stock
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
www.schrodinger.com- Employees
- 850
- IPO / List date
- Feb 6, 2020
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds SDGR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2024-06-30 | 87,113 | $1.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SDGR yet.
